Non-small cell lung cancer (NSCLC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

June 02 09:07 2021
Non-small cell lung cancer (NSCLC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Non-small cell lung cancer (NSCLC)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-small cell lung cancer (NSCLC), historical and forecasted epidemiology as well as the Non-small cell lung cancer (NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Non-small cell lung cancer (NSCLC)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Non-small cell lung cancer (NSCLC)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-small cell lung cancer (NSCLC), historical and forecasted epidemiology as well as the Non-small cell lung cancer (NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

According to the Society, out of the total lung cancer cases, approximately 80─85% of lung cancers are NSCLC. The main subtypes of NSCLC include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

According to the research study, the 5-year survival rates after surgical resection are 60%–80% for Stage I NSCLC and 30%–50% for Stage II NSCLC patients. More than 70% of NSCLC patients are diagnosed in advanced stages of metastatic disease. Also, the 5-year survival rate varies between 10% to 15% for Stage IIIA disease and 2% to 5% for Stage IIIA with mediastinal involvement. Stage IIIB NSCLC signifies approximately 17.6% of all lung cancers with a 5-year survival rate of 3% to 7%.

According to the research study, the authors utilized data from the national database of hospital-based cancer registries. The authors of this study have taken the average of age-wise diagnostic cases for the analysis in this study. In this study, 39.53%, 8.93%, 16.18%, and 32.60% of cases were observed for Stage I, Stage II, Stage III, And Stage IV cases were observed for NSCLC.

Key benefits of the report:

1.The Non-small cell lung cancer (NSCLC) market report covers a descriptive overview and comprehensive insight of the Non-small cell lung cancer (NSCLC) epidemiology and Non-small cell lung cancer (NSCLC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Non-small cell lung cancer (NSCLC) market report provides insights into the current and emerging therapies.

3.Non-small cell lung cancer (NSCLC) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Non-small cell lung cancer (NSCLC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-small cell lung cancer (NSCLC) market.

Request for sample pages: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

Non-small cell lung cancer (NSCLC): Overview

Most people with lung cancer have NSCLC. Although serious, treatment can sometimes prevent it from spreading. There are things you can do to help you feel better, too. People who smoke or breathe in large amounts of smoke are more likely to get NSCLC. Most of them are over 65 years old.

There are four types of NSCLC tumours:

1. Adenocarcinoma Starts in cells in your air sac making mucus and other substances, usually on the outside of your lungs. The most common form of lung cancer in smokers and non-smokers and in people under 45 years of age. It usually grows slower than other lung cancers.

2. Squamous cell (epidermoid) carcinoma begins in cells that line the inner airways of the lungs. About a quarter of lung cancer is this type.

3. Carcinoma of large (undiagnosed) cells grows and spreads very quickly which can make it difficult to treat. About 10% of lung cancer.

4. Adenosquamous carcinoma is rare and usually develops on the outer part of the lungs. Smoking can increase the risk of its development.

The treatment your doctor prescribes will depend on the extent of your lung cancer.

The key players involved in the Non-small cell lung cancer (NSCLC) market:

 

  1. Novartis Pharmaceuticals
  2. AbbVie
  3. Janssen Pharmaceuticals
  4. Xcovery
  5. Eli Lilly and Company
  6. Sanofi
  7. Pfizer
  8. Astellas Pharma/Seattle Genetics
  9. Takeda Pharmaceuticals
  10. Novartis Pharmaceuticals
  11. Merck/Pfizer
  12. AbbVie
  13. Mirati Therapeutics/Bristol-Myers Squibb/Beigene
  14. Amgen
  15. Incyte Corporation
  16. Amgen
  17. Merck

 

The launch of the emerging therapies is expected to significantly impact the  Non-small cell lung cancer (NSCLC) treatment scenario in the upcoming years:-

Drug covered

  1. Nazartinib/EGF816 and Capmatinib/INC280
  2. Telisotuzumab Vedotin
  3. JNJ-61186372/JNJ-6372
  4. Ensartinib/X-396
  5. Selpercatinib
  6. SAR408701
  7. Braftovi+ Mektovi
  8. PADCEV
  9. TAK-788
  10. Canakinumab
  11. Avelumab
  12. Veliparib
  13. Sitravatinib (MGCD516)
  14. AMG 510
  15. INCMGA00012/MGA012
  16. Romiplostim
  17. TEPMETKO (tepotinib)

Request a free sample report @https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Non-small cell lung cancer (NSCLC) Patient Share (%) Overview at a Glance

5. Non-small cell lung cancer (NSCLC) Market Overview at a Glance

6. Non-small cell lung cancer (NSCLC) Disease Background and Overview

7. Non-small cell lung cancer (NSCLC) Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-small cell lung cancer (NSCLC) 

9. Non-small cell lung cancer (NSCLC) Current Treatment and Medical Practices

10. Unmet Needs

11. Non-small cell lung cancer (NSCLC) Emerging Therapies

12. Non-small cell lung cancer (NSCLC) Market Outlook

13. Country-Wise Non-small cell lung cancer (NSCLC) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Non-small cell lung cancer (NSCLC) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Non-small cell lung cancer (NSCLC)-Pipeline Insights, 2021

“Non-small cell lung cancer (NSCLC)-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-small cell lung cancer (NSCLC) market. A detailed picture of the Non-small cell lung cancer (NSCLC) pipeline landscape is provided, which includes the disease overview and Non-small cell lung cancer (NSCLC) treatment guidelines.

Non-small cell lung cancer-Epidemiology Forecast to 2030

DelveInsight’s ‘Non-small cell lung cancer-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-small cell lung cancer {;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author